| 960368-11-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• CAS: 960368-11-0
• 化学式: C₂₈H₃₂F₄N₂O₃
• 分子量: 520.567
• InChiKey: ZEHMTRACVGXAFW-YGPDHOBYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.35
• 重原子数：
  37.0
• 可旋转键数：
  8.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  83.63
• 氢给体数：
  2.0
• 氢受体数：
  3.0

反应信息

• 作为产物：
  描述：

  N-((1r,4S)-4-(2-cyanoethyl)-4-(4-fluorophenyl)cyclohexyl)-N-cyclopropyl-4-((S)-1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide 在 potassium hydroxide 作用下， 以 叔丁醇 为溶剂， 生成
  参考文献：
  名称：

  Synthesis and optimization of novel 4,4-disubstituted cyclohexylbenzamide derivatives as potent 11β-HSD1 inhibitors

  摘要：

  The synthesis and SAR of a series of 4,4-disubstituted cyclohexylbenzamide inhibitors of 11 beta-HSD1 are described. Optimization rapidly led to potent, highly selective, and orally bioavailable inhibitors demonstrating efficacy in both rat and non-human primate ex vivo pharmacodynamic models. (c) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.10.129

文献信息

• Benzamide derivatives and uses related thereto
  申请人：Powers P. Jay

  公开号：US20070299080A1

  公开（公告）日：2007-12-27

  Benzamide derivatives of formula I are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and n are as defined herein.

  公式I的苯甲酰胺衍生物已被描述，并具有治疗效用，特别是在治疗糖尿病、肥胖和相关疾病和紊乱方面：其中R1、R2、R3、R4、R5、R6、R7、R8和n如本文所定义。
• BENZAMIDE DERIVATIVES AS MODULATORS OF 11BETA-HSD1 FOR TREATING DIABETES AND OBESITY
  申请人：Amgen Inc.

  公开号：EP2044004B1

  公开（公告）日：2012-08-15
• US8772296B2
  申请人：——

  公开号：US8772296B2

  公开（公告）日：2014-07-08
• [EN] BENZAMIDE DERIVATIVES AND USES RELATED THERETO<br/>[FR] DÉRIVÉS DE BENZAMIDE ET UTILISATIONS ASSOCIÉES À CEUX-CI
  申请人：AMGEN INC

  公开号：WO2007145835A2

  公开（公告）日：2007-12-21

  [EN] Benzamide derivatives of formula ( I ) are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders, formula (I), wherein R¹, R ², R ³, R ⁴, R ⁵, R ⁶, R ⁷, R ⁸, and n are as defined herein.
  [FR] La présente invention concerne des dérivés de benzamide de formule (I) ayant une utilité thérapeutique, en particulier dans le traitement du diabète, de l'obésité et de pathologies et troubles apparentés, formule (I), où R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, et n sont comme présentement défini.
• Synthesis and optimization of novel 4,4-disubstituted cyclohexylbenzamide derivatives as potent 11β-HSD1 inhibitors
  作者：Daqing Sun、Zhulun Wang、Seb Caille、Michael DeGraffenreid、Felix Gonzalez-Lopez de Turiso、Randall Hungate、Juan C. Jaen、Ben Jiang、Lisa D. Julian、Ron Kelly、Dustin L. McMinn、Jacob Kaizerman、Yosup Rew、Athena Sudom、Hua Tu、Stefania Ursu、Nigel Walker、Maren Willcockson、Xuelei Yan、Qiuping Ye、Jay P. Powers

  DOI：10.1016/j.bmcl.2010.10.129

  日期：2011.1

  The synthesis and SAR of a series of 4,4-disubstituted cyclohexylbenzamide inhibitors of 11 beta-HSD1 are described. Optimization rapidly led to potent, highly selective, and orally bioavailable inhibitors demonstrating efficacy in both rat and non-human primate ex vivo pharmacodynamic models. (c) 2010 Elsevier Ltd. All rights reserved.